Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) announced its Q3 2021 financial results, showcasing a remarkable 176% revenue growth year-over-year, reaching $5.6 million. Pro-forma gross margin improved to 45% from 26.9% a year prior. Despite robust revenue growth, the company reported an operating loss of $22.5 million, up 240.8% from Q3 2020. Dario secured 47 contracts to date, with a billion-dollar pipeline, primarily focused on multi-condition digital health solutions. The firm is well-funded with $51.3 million in cash, supporting its growth strategy in the competitive digital therapeutics market.

DarioHealth Corp. (Nasdaq: DRIO) has appointed Jerrod Helms as Chief Commercial Officer to enhance its growth in employer, payer, and provider markets amid significant commercial acceleration. Mr. Helms, with extensive sales leadership experience in healthcare, joins from Ginger and Headspace. The appointment aims to capitalize on rising demand for Dario's multi-chronic digital therapeutic solutions. The company is optimistic about expanding its market presence and achieving accelerated growth moving into 2022.

DarioHealth Corp. (NASDAQ: DRIO) is set to release its financial results for Q3 2021 on November 15, 2021, after trading. A conference call will occur on November 16, 2021, at 8:30 AM ET. Key executives including CEO Erez Raphael will lead the call.

Investors can dial in using the numbers 877-451-6152 (US) or 201-389-0879 (international). The webcast will be accessible [here](https://viavid.webcasts.com/starthere.jsp?ei=1511170&tp_key=13b2851117). Replays will be available until December 16, 2021.

On November 5, 2021, DarioHealth Corp. (Nasdaq: DRIO) announced its participation in two upcoming investor conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, featuring a fireside chat with CEO Erez Raphael at 9:40 am EST. The second event is the Craig-Hallum 12th Annual Alpha Select Conference on November 16. Interested parties can access the live and archived webcasts of these events on DarioHealth's investor website. DarioHealth is at the forefront of digital therapeutics, offering comprehensive solutions for chronic condition management.

DarioHealth Corp. (Nasdaq: DRIO) announced a strategic partnership with a national benefits administrative platform to deliver its digital therapeutic solutions, beginning January 2022. This collaboration aims to provide integrated chronic condition management solutions, including diabetes and hypertension, to a broad employer base. Dario's platform focuses on improving health outcomes and lowering costs for users through an AI-driven journey engine, enhancing accessibility in seven languages. This partnership is expected to expand Dario's visibility among employers seeking scalable health solutions.

DarioHealth Corp. (Nasdaq: DRIO) has secured contracts with two regional providers in Hawaii and Georgia for its Remote Patient Monitoring (RPM) services, enhancing its presence in the RPM market. These agreements focus on managing diabetes and hypertension, addressing common chronic conditions. Dario currently supports over 197,000 members on its digital therapeutics platform, showcasing its credibility among providers. The company's innovative platform offers personalized solutions, appealing to healthcare providers seeking effective patient engagement.

DarioHealth has partnered with Virgin Pulse to provide its digital therapeutic solutions to global employers and health plans. This collaboration allows eligible employees to access Dario's services through Virgin Pulse's Homebase for Health® platform. The integrated solutions support various chronic conditions, utilizing AI and extensive user data for personalized health management. Virgin Pulse aims to enhance member health outcomes by simplifying access to Dario's services, which are expected to decrease healthcare costs and improve clinical results.